GlassScriptPhysician profile
Michael Clark Roberts
NPI 1508829730
$3,579.38
in general payments reported to CMS, 2019-2025
28 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $292 · 2021: $511 · 2022: $809 · 2023: $826 · 2024: $400 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $946.44 | 2019-2025 | |
| Boston Scientific Corporation | $628.57 | 2019-2024 | Avvigo Guidance System, Watchman Access System, Watchman Flx |
| Medtronic, INC. | $274.51 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Shockwave Medical, INC | $265.58 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $239.01 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $208.26 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $190.61 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.78 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $99.77 | 2024-2025 | Onpattro |
| Novo Nordisk INC | $97.25 | 2019-2025 | Ozempic, Wegovy |
| Chiesi USA, INC. | $65.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $61.86 | 2020-2022 | |
| Pfizer INC. | $60.64 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $53.60 | 2019 | |
| Biotronik INC. | $27.40 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27.37 | 2020-2023 | Praluent, Evkeeza |
| Sumitomo Pharma America, INC. | $26.96 | 2025 | Gemtesa |
| Philips North America LLC | $24.63 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.62 | 2025 | Jardiance |
| Amarin Pharma, INC. | $24.21 | 2019 | |
| Laborie Medical Technologies Corp. | $23.58 | 2024 | Endosheath Technology |
| Cvrx, INC. | $21.66 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $18.40 | 2023 | Arcalyst |
| Astellas Pharma US INC | $14.04 | 2019 | |
| Esperion Therapeutics, INC. | $11.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.12 | 2019 | |
| Medtronic Vascular, INC. | $10.81 | 2019 | |
| Cardiovascular Systems INC. | $3.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.